Activity Report 2022

CIC bioGUNE - Centro de Investigación Cooperativa en Biociencias

 

Scientific Programmes

Research lines

Cancer

Metabolic diseases

Infectious diseases

Rare diseases

The cutting-edge scientific activity of CIC bioGUNE researchers explores the interface between Chemistry and Biomedicine, with emphasis on Structural, Molecular and Cell Biology. An integrative Bioinformatics Program extrapolates relevant conclusions from basic science.

Metabolism and Cell Signaling in Disease

  • Personalized medicine
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Liver Diseases
  • Rare Diseases
  • Biomarkers for Diagnosis
  • Biomarkers for Prognosis
  • Drug Design and Discovery

Molecular Recognition and Host-Pathogen

  • Rare Diseases
  • Homeostasis
  • Viral Infections
  • Bacterial Infections
  • Prion Disease
  • Tick-Borne Disease
  • Immune Response
  • Drug Design and Discovery

Platforms

  • NMR Spectroscopy
  • Macromolecular Crystallography
  • Electron Microscopy
  • Genome Analysis
  • Proteomics
  • Metabolomics
  • Animal Facility

 

Generation of
knowledge

Technology
transfer

Commercialization of
results

Scientific Programmes
Metabolism & Cell Signaling in Disease

Brain

Breast

Colon

Liver

Prostate

  1. Target discovery and evaluation of their therapeutic potential
  2. Cancer and more: Identification of biomarkers with potential diagnostic value
  3. Novel therapies against rare diseases
  4. The molecular basis of fibrosis
  5. Nonalcoholic steatohepatitis

The Research Programmes
Molecular Recognition & Host-Pathogen Interactions

Parasites

Vaccines

Antibiotics

Membrane remodelling

Animal and plant viruses

  1. Bacterial and Viral Infections: Vaccines for human and animal health
  2. Mechanisms of membrane remodelling during microbial invasion and propagation
  3. Plant vaccines and transgenics
  4. Antibiotics research and molecular characterization

The Research Programmes
Technology Platforms

Genome Analysis Platform

Proteomics Platform

Metabolomics Platform

Animal Facility

Antibodies Production

Drug Repositioning & Discovery

Nuclear Magnetic Resonance

Macromolecular Crystallography

Electron Microscopy Platform

Collaboration Models

Services
R&D Collaborations
Consulting

About Us

flecha abajo-derecha

Mission:

Conducting research of excellence in the field of the life sciences, covering the entire value of R&D&i, including technology transfer and commercial exploitation of the generated scientific results.

flecha derecha-abajo

Strategic Challenges:

  • Research of excellence
  • Technology Transfer
  • Collaboration with RVCTI agents
  • International recognition
  • Training and promotion of research talent
  • Attraction and retention of talent
  • Communication and Outreach
  • Excellence in Management

Strategy:

Commitment to specialization and excellence

flecha derecha-arriba

Competitiveness:

  • Leading infrastructures
  • Human Resources
  • Technical and administrative support
  • Competitive salaries
  • Goal-Fulfillment Incentives
flecha abajo-izquierda

Personnel

Personnel 2022.12.31: 0

FTE (2022): 0

Permanent (FTE): 0 (46.3%)

Gender Distribution

  • 0% Female
    127
  • 0% Male
    94
  • LISMI - Law of Social Integration of the Handicapped
    4

221 Total CIC bioGUNE Personnel

  • 0% Research
    183
  • 0% Administration and Services
    38

 

Researchers Distribution by Professional Category

    % Woman Man
  Researchers 133 73 71 62
  • Principal investigators/Platform Managers 20 11 7 13
  • Postdoctoral Researchers/Research Assistant/Specialist 51 28 31 20
  • PhD Candidates 62 34 33 29
  Technicians 50 27 37 13

Research Distribution by Geographic Origin

Research Distribution by Geographic Origin

Austria 1
Germany 3
Greece 1
Holland 1
Italy 13
Poland 1
Russia 1
Romania 1
Spain 182
United Kingdom 1
America 14
Asia 2
  • 0% Spain
    182 researchers
  • 0% Rest of Europe
    23 researchers
  • 0% America
    14 researchers
  • 0% Asia
    2 researchers

Funding

Total 2022 R&D Budget: 0 million €

Running R&D Projects: 0

New R&D Projects: 0

  • 0 % Competitive Public Funding
  • 0 % Core Funding
  • 0 % Basque Government Departments
    11.938 k€
  • 0 % R&D Contracts, Research Services & Others
    7.674 k€
  • 0 % MINECO & MEDC (Government of Spain)
    3.030 k€
  • 0 % EU & International Projects
    1.888 k€

Technology Transfer

Economic Activity: 6.574.569

  • Basque Country: 0%
  • National: 0%
  • International: 0%

New Research Contracts 0

0 New Patent Families (4 EPO, 1 USTPO)

0 Active Patents

0 Technology Transfer Agreements

0 Spin-Off

 

Active Patents

 

Personnel

personnel

Social Commitment
Talent opportunity

NEW CALL Closing october 2022

CIC bioGUNE Initiative

Fellowships Fundación ONCE - CIC bioGUNE New Applications Awarded
  • Predoctoral Trainee
  • Postdoctoral Trainee

Funding Applications

140 Applications

Basque Country
0%

18 Applications
  • 0 Research Projects
  • 0 Human Resources
  • 0 Research stage
  • 0 Infrastructure (equipment)

Spain
0%


70 Applications
  • 0 Research Projects
  • 0 Human Resources
  • 0 Research Networks
  • 0 Research Awards
  • 0 Strategic Projects
  • 0 Research Stage

Europe 0%
International 0%


43 European Applications
  • 0 Research Projects
  • 0 Human Resources
  • 0 Research Networks
  • 0 Research Stages
9 International Applications
  • 0 Research Projects

49 New Applications Awarded

Basque Country
0%

6 Applications
  • 0 Research Projects
  • 0 Human Resources
  • 0 Equipment
Spain
0%


32 Applications
  • 0 Research Projects
  • 0 Human Resources
  • 0 Research Awards
  • 0 Strategic Projects
  • 0 Research Stage
Europe 0%
International 0%


9 European Applications
  • 0 Research Projects
  • 0 Research Stage
2 International Applications
  • 0 Research Projects

Competitive Funding

Key Action
Elkartek 2022: A. Palazón & M. Vivanco, with many others

Desarrollo de métodos diagnósticos y nuevas terapias en la era de la medicina de precisión en cáncer
Developing new diagnostic methods and novel therapies for precision medicine in cancer

Competitive Funding

Gobierno vasco, departamento de desarrollo económico, sostenibilidad y medio ambiente

ELKARTEK 2022

Coordinator: CIC bioGUNE

  • Small Molecules
  • Cell Therapy
  • Glycomimetics
  • RNA Therapy
  • Biologics
Coordinators: Asís Palazón & María Vivanco

Competitive Funding
Human Resources

Key Successful Applications

Spain

Juan de la Cierva
Program

Investigator:
María Elena Laugieri
Supervisor:
Jesús Jiménez-Barbero

Ramón y Cajal
Program

Investigator:
Gabriel Ortega
Precision Medicine &
Metabolism Lab

Sello de Excelencia ISCIII-HEALTH

Investigator:
Antonela S. Stagnoli
Supervisor:
Nicola GA Abrescia
Investigator:
Agustina Creus
Supervisor:
Malu Martínez-Chantar

Euskadi

Investigator:
Luca Unione
Chemical Glycobiology Lab
Investigator:
Oihana Iriondo Martinez de Zuazo
Cancer Cell Signaling & Metabolism Lab

Private

Investigator

Investigator:
Amaia Zabala
Director: Arkaitz Carracedo

AECC Predoctoral
– JP Bizkaia

Investigator:
Naiara Gutiez
Supervisor: Juan Anguita

Competitive Funding

Europe


Nicola GA Abescia

Coordinator:

HORIZON-CL6-2021-FARM2FORK-01

SPIDVAC - Improved control of priority animal diseases: Novel vaccines and companion diagnostic tests for African horse sickness, peste des petits ruminants and foot-and-mouth disease


Óscar Millet

Coordinator:

HORIZON-CL6-2022-FARM2FORK-01

CoDiet - Combatting diet related non-communicable disease through enhanced surveillance


Óscar Millet

Coordinator:

HORIZON-INFRA-2021-DEV-01

R-NMR - Remote NMR (R-NMR): Moving NMR infrastructures to remote access capabilities


Jesús Jiménez-Barbero

Coordinator:

HORIZON-WIDERA-2021-ACCESS-03

GlycoTwinning - Building Networks to Excel in Glycosciences


Juan Manuel Falcón

Coordinator:

HORIZON-WIDERA-2021-ACCESS-03

EVCA - Centre for Excellence in Diagnostic and Advanced Therapeutics based on Extracellular Vesicles


Juan Manuel Falcón

Coordinator:

HORIZON-HLTH-2022-STAYHLTH-02-01

Halt-RONIN -Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies

0 M€ CIC bioGUNE

Spain


Proyectos Generación de Conocimiento
Funded projects: 0
Total Grant Amount (3 years): 0 M€
Doctoral Candidates: 0 FPI

Gonzalo Jiménez-Osés, Jesús Jiménez-Barbero, Joaquín Castilla, Juan Anguita, Juan Manuel Falcón, Mikel Valle, Nicola GA Abrescia, Óscar Millet


Asís Palazón


Proyectos Estratégicos orientados a la transición ecológica y digital

Desarrollo de una plataforma analítica sostenible para la salud digital de la era post-pandémica

Private Funding


Creutzfeldt-Jakob Disease Foundation


Joaquín Castilla


Grant Applications

Development and characterization of the fastest animal model able to propagate GSS prions faithfully



Alberto Fernández-Tejada


AECC Lab

Development of a cancer vaccine platform based on synthetic saponin adjuvants and tumor peptide antigens


Institut Germans Trias i Pujol


Malu Martínez-Chantar


AECC Coordinados

Precision medicine for hepatoblastoma: identification of novel therapies and predictive biomarkers using a unique EU biorepository


Juan Manuel Falcón


Research Grant to Promote Diversity

Exosomes in Alzheimer's Disease from a metabolic point of view

Technology Transfer Projects
Euskadi


Malu Martnez-Chantar

siRNA-GalNAC for Liver Disease


scar Millet

Metabolic Age Product

Competitive Funding

Technology Transfer Projects

Spain


Pruebas de Concepto, I+D+i


Asís Palazón

Óscar Millet

Jesús Jiménez-Barbero

Gonzalo Jiménez-Osés

Coordinator


Óscar Millet


Colaboración Público-Privada

Desarrollo de una formulación oral de ciclopirox para el tratamiento de la porfiria eritropoyética congénita

Europe


Asís Palazón


ERC Proof of Concept

FIH-IO - Development of a first-in-class inhibitor of FIH for cancer immunotherapy


Alberto Fernández Tejada


ERC Proof of Concept

ADJUVACCINE - Development of a marketable adjuvant candidate for vaccine applications

Spain:
Complementary Plans

Biotecnología aplicada a la salud
Gobierno de España, plan de  Recuperación, Transformación y Resilienciad

Click to view in PDF
Spain: Complementary Plans

Subvenciones directas a las comunidades autónomas para financiar la incorporación a programas de los Planes Complementarios de I+D+I que forman pare del componente 17 del Plan de Recuperación, Transformación y Resiliencia, denominado "Reforma Institucional y fortalecimiento de las capacidades del Sistema Nacional de Ciencia, Tecnología e Innovación".

Competitive Funding
Severo Ochoa 2021

Awarded in 2022

0 M€
10 new contracts for PhD candidates
Gobierno de España, plan de  Recuperación, Transformación y Resilienciad

Click to view in PDF
Trainig action: BG Academy

Accreditations

Quality System Management

ISO 9001

Newborns urine sample screening for the detection of inborn errors of metabolism.

2nd follow up audit

Provision of quality control service of samples by electron microscopy.

Acreditation audit Tentative date First half 2023

ISO 13485

Design, development & manufacture of software to aid in the diagnosis of newborn congenital metabolic errors

2st follow up audit

Prior Operating License (in the process of submitting an application)

UNE 166002

Design and development of R+D projects to discover new drugs nd biomarkers for diagnosis and prognosis.

Re-accreditation audit & update to 2021 version

UNE166002 R&D Management

Click on the image to see it enlarged in pdf

Certificado SGS ENAC

AENOR 166002

Transition to UNE166002:2021

Euskadi: Industrial Competitiveness
& Sustainability Projects

Commitment of the 22 participants

17 companies 5 hospitals 2 sectorial cluster/associations 3 scientific-technological entities
Contribute their skills:

Research, technological development, industrial design, manufacturing, certification, intellectual protection and technological surveillance


Solución integral de diagnóstico y terapias para la gestión de la COVID-19 y futuras pandemias

Training: COMPLIANCE

What does compliance mean?


  • Risk management system and internal control

Who is this training for?


  • On-site training for all members of CIC bioGUNE

Which will be the main contents?


  • Criminal liability of CIC bioGUNE as a legal person
  • Implemented system in CIC bioGUNE: risk assessment, politics, procedures, Ethics Channel, dissemination on the corporate website

Which are the essential elements of the compliance system I should be aware of?


  • Code of Ethics and Conduct
  • Protocol for action against Conflicts of Interest
  • Ethics Channel

Which are some of the main risks in the performance of scientific activity?


  • Unethical behaviour
  • Situations of gender inequality
  • Scientific Conflict of Interest
  • Management of public funds by Principal Investigators
  • Gifts, incentives, special attention or privileges

Activities

Equality Plan

March 22 - Equality Comission
8 March 22 - Competitions
Título: Torres Gemelas
Autora: Coralia Peréz

Torres Gemelas

Título: Planeta 290520L
Autora: Laura Bozal
PLANETA 290520L

Día0-9:00h: Aterrizaje planeta 29052020L-TIERRA. Viajo en forma acorporal. Decido adoptar una apariencia análoga a los autóctonos. Consulto el Catálogo de formas terrestres-CFT. Existen dos complexiones a elegir: los que no extirpan voluntariamente sus pelos y, sin ser necesariamente más inteligentes, reciben más objetos de papel/metal denominados dinero por su trabajo; y las que expulsan un líquido rojo una semana al mes u otro ser humano chiquitín con dolor y son peor remuneradas, aunque ejecuten las mismas funciones.

Sin duda, decido personarme en los primeros, denominados hombres. Y me pregunto, ¿quién querría pertenecer a las segundas en este planeta tan extraño?

Click on the image to see enlarged in pdf

Reto 25N

Acoso Sexual vs Acoso por razón de sexo
¿Sabes identificarlos?

Scientific Outreach

Bulletin

Click on the images to see them enlarged in pdf

Scientific Annual Review

Click on the image to see it enlarged in pdf

Scientific Annual Review

NEBTs

2016. Discovery of innovative "first-in-class" therapies, based on the principle of pharmacological chaperones, for the treatment of rare and ultra-rare diseases. 1 ODD (EMA & FDA) entering in Phase I-IIa in USA.

2020. Innovation & development: exploitation of technologies for processing and analysis of biological, biochemical, biotechnological & medical data.

2022

Focused on the development of cellular immunotherapies for the treatment of solid tumors.

Zelula Biopharma - Noticia

Collaboration

Tech Boost Progam, CIC bioGUNE


Asís Palazón

Master Final Degree
Entrepreneurship in Biotech

Business Plan, Opportunity Analysis in CAR-T

Research, Development & Innovation in biomedical technology

Renewal of Collaboration Agreement, March 2022

Awards and Recognitions


National Award for Young Investigators in Biology "Margarita Salas"



Óscar Millet

German-Spain Award in Chemistry
Hermanos Elhúyar - Goldschmidt


Arkaitz Carracedo

Research Award
Fundación Jesús Serra

Key Facts

CIC bioGUNE receives again the Severo Ochoa Center of Excellence in 2022. The purpose of this distinction is to give visibility to research centers, in any scientific area, that demonstrate impact and scientific leadership at an international level and actively collaborate with their social and business environment.

Dr. Arkaitz Carracedo receives the National Margarita Salas Award for Young Scientists in the field of Biology.

The AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) accreditation for CIC bioGUNE is renewed and the accreditations of the UNE 166002:2021, ISO 9011:2015 and ISO 13485:2016 standards are maintained.

Agreements and Contracts: The Collaboration Agreement between CIC bioGUNE and the Tekniker Foundation has been renewed for carrying out joint projects on Research, Development and Innovation in biomedical technology.

On April 8, 2022 Bruker Española, S.A. and CIC bioGUNE signed a contract for the acquisition of a superconducting magnet for a NMR spectrometer with a magnetic field of 23.58 Teslas (1 GHz) to focus on Precision Medicine projects.

Osasunberri consortium, which gathers 23 Basque entities, has been created, funded by the Basque Government through the Program for the Promotion of Industrial Competitiveness & Sustainability. Its objective is the search for diagnostic solutions and therapies for the management of future pandemics.

Staff and HR: A new call for the Talent Opportunity Scholarship Program has been launched held, cofunded between the ONCE Foundation and CIC bioGUNE for the hiring of a postdoctoral fellow and a predoctoral fellow

Two new IKERBASQUE Research Fellows have joined the Chemical Glycobiology (Dr. Luca Unione) and Cancer Cell Signaling & Metabolism (Dr. Oihana Iriondo) laboratories.

Dr. Oscar Millet is recognized with the Elhuyar-Goldschmit Award from the German Chemical Society.

New technology-based companies (NEBT): On June 1, 2022, a new spin-off company, ZELULA BIOPHARMA, SL, has been created. Its corporate purpose is research, development, innovation, production, manufacturing, marketing, exploitation, distribution, import and/or export of pharmaceutical, biotechnological and health products, as well as the provision of associated services, with a strong focus on CAR-T therapies.

Diffusion: EUROMAR 2024 conference, the European Magnetic Resonance Meeting, will be hosted by CIC bioGUNE at Bilbao, under the presidency of Dr. Oscar Millet. EUROMAR is the main meeting in the field of NMR worldwide with representation of scientists from the five continents. It covers all aspects of NMR and MRI, including biomedical and clinical applications. The attendance of 1,000 scientists and the presentation of 400 posters are expected.

Funding:

The Ministry of Science and Innovation, through the State Program for Research, Development & Innovation Oriented to the Challenges of Society has granted CIC bioGUNE eight projects for a total amount of €1,966,250.

Moreover, CIC bioGUNE has obtained additional competitive funding through the following calls:

Ministry of Science and Innovation:
  • Four "Proofs of Concept" projects.
  • One "Ecological and Digital Transition" strategic project.
  • One "Public-Private Partnership" project.
  • Regarding personnel, Four Juan de Cierva and one Ramón y Cajal contracts.
Institute of Health Carlos III (ISCIII):
  • Two "MSCA-ISCIII Health Seal of Excellence" projects

A Proposal on Precision Medicine from CIC bioGUNE has also been funded through the Complementary Plans for R+D+i in the field of Biotechnology applied to Health, within the Recovery, Transformation and Resilience Plan, dubbed "Institutional Reform and strengthening of the capacities of the National Science, Technology and Innovation System.

Research Activity

Regarding research activity, the key numbers for 2022 were:

Projects:
  • 31 New research projects
  • 104 Ongoing projects
Scientific production:
  • 187 Publications, with 153 in Q1 and 66 in D1 Journals
  • 9372 citations received
  • 19 PhD Thesis were defended with 78 running PhD candidates
  • 143 impacts in press, radio, and TV media
Intellectual property:
  • 4 EPO, 3 PCT, and 5 Industrial Secrets

Publications

 
12
Average
Impact Factor

Highlights

Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis.

Fondevila MF, Fernandez U, Heras V, Parracho T, Gonzalez-Rellan MJ, Novoa E, Porteiro B, Alonso C, Mayo R, da Silva Lima N, Iglesias C, Filliol AA, Senra A, Delgado TC, Woodhoo A, Herrero L, Serra D, Prevot V, Schwaninger M, López M, Dieguez C, Millet O, Mato JM, Cubero FJ, Varela-Rey M, Iruzubieta P, Crespo J, Martinez-Chantar ML, Schwabe RF, Nogueiras R.

J Hepatol. 2022 Jul;77(1):15-28. doi: 10.1016/j.jhep.2022.02.003. Epub 2022 Feb 12. PMID: 35167910.

Targeting NAE1-mediated protein hyper-NEDDylation halts holangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

Olaizola P, Lee-Law PY, Fernandez-Barrena MG, Alvarez L, Cadamuro M, Azkargorta M, O'Rourke CJ, Caballero-Camino FJ, Olaizola I, Macias RIR, Marin JJG, Serrano-Maciá M, Martinez-Chantar ML, Avila MA, Aspichueta P, Calvisi DF, Evert M, Fabris L, Castro RE, Elortza F, Andersen JB, Bujanda L, Rodrigues PM, Perugorria MJ, Banales JM.

J Hepatol. 2022 Jul;77(1):177-190. doi: 10.1016/j.jhep.2022.02.007. Epub 2022 Feb 23. PMID: 35217064

Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

da Silva Lima N, Fondevila MF, Nóvoa E, Buqué X, Mercado-Gómez M, Gallet S, González-Rellan MJ, Fernandez U, Loyens A, Garcia-Vence M, Chantada-Vazquez MDP, Bravo SB, Marañon P, Senra A, Escudero A, Leiva M, Guallar D, Fidalgo M, Gomes P, Claret M, Sabio G, Varela-Rey M, Delgado TC, Montero-Vallejo R, Ampuero J, López M, Diéguez C, Herrero L, Serra D, Schwaninger M, Prevot V, Gallego-Duran R, Romero-Gomez M, Iruzubieta P, Crespo J, Martinez-Chantar ML, Garcia-Monzon C, Gonzalez-Rodriguez A, Aspichueta P, Nogueiras R

J Hepatol. 2022 Jan;76(1):11-24. doi: 10.1016/j.jhep.2021.09.008. Epub 2021 Sep 21. PMID: 34555423.

Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure

Zhang IW, Curto A, López-Vicario C, Casulleras M, Duran-Güell M, Flores-Costa R, Colsch B, Aguilar F, Aransay AM, Lozano JJ, Hernández-Tejero M, Toapanta D, Fernández J, Arroyo V, Clària J

J Hepatol. 2022 Jan;76(1):93-106. doi: 10.1016/j.jhep.2021.08.009. Epub 2021 Aug 25. PMID: 34450236

Controlled masking and targeted release of redox-cycling ortho- quinones via a C-C bond-cleaving 1,6-elimination

Dunsmore L, Navo CD, Becher J, de Montes EG, Guerreiro A, Hoyt E, Brown L, Zelenay V, Mikutis S, Cooper J, Barbieri I, Lawrinowitz S, Siouve E, Martin E, Ruivo PR, Rodrigues T, da Cruz FP, Werz O, Vassiliou G, Ravn P, Jiménez-Osés G, Bernardes GJL

Nat Chem. 2022 Jul;14(7):754-765. doi: 10.1038/s41557-022-00964-7. Epub 2022 Jun 27. PMID: 35764792; PMCID: PMC9252919

Angiocrine polyamine production regulates adiposity

Monelli E, Villacampa P, Zabala-Letona A, Martinez-Romero A, Llena J, Beiroa D, Gouveia L, Chivite I, Zagmutt S, Gama-Perez P, Osorio-Conles O, Muixi L, Martinez-Gonzalez A, Castillo SD, Martín-Martín N, Castel P, Valcarcel-Jimenez L, Garcia-Gonzalez I, Villena JA, Fernandez-Ruiz S, Serra D, Herrero L, Benedito R, Garcia-Roves P, Vidal J, Cohen P, Nogueiras R, Claret M, Carracedo A, Graupera M

Nat Metab. 2022 Mar;4(3):327-343. doi: 10.1038/s42255-022-00544-6. Epub 2022 Mar 14. PMID: 35288722

Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, Martín-Martín N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazón A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH

J Clin Invest. 2022 Apr 1;132(7):e148667. doi: 10.1172/JCI148667. Erratum in: J Clin Invest. 2022 Oct 3;132(19): PMID: 35192545; PMCID: PMC8970678

HIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes

Ilegems E, Bryzgalova G, Correia J, Yesildag B, Berra E, Ruas JL, Pereira TS, Berggren PO

Sci Transl Med. 2022 Mar 30;14(638):eaba9112. doi: 10.1126/scitranslmed.aba9112. Epub 2022 Mar 30. PMID: 35353540

ChemPert: mapping between chemical perturbation and transcriptional response for non- cancer cells

Zheng M, Okawa S, Bravo M, Chen F, Martínez-Chantar ML, Del Sol A

Nucleic Acids Res. 2023 Jan 6;51(D1):D877-D889. doi: 10.1093/nar/gkac862. PMID: 36200827; PMCID: PMC9825489

Immobilization of Biantennary N-Glycans Leads to Branch Specific Epitope Recognition by LSECtin

Bertuzzi S, Peccati F, Serna S, Artschwager R, Notova S, Thépaut M, Jiménez- Osés G, Fieschi F, Reichardt NC, Jiménez-Barbero J, Ardá A

ACS Cent Sci. 2022 Oct 26;8(10):1415-1423. doi: 10.1021/acscentsci.2c00719. Epub 2022 Sep 20. PMID: 36313162; PMCID: PMC9615123

A glutamine-based single α-helix scaffold to target globular proteins

Escobedo A, Piccirillo J, Aranda J, Diercks T, Mateos B, Garcia-Cabau C, Sánchez-Navarro M, Topal B, Biesaga M, Staby L, Kragelund BB, García J, Millet O, Orozco M, Coles M, Crehuet R, Salvatella X

Nat Commun. 2022 Nov 18;13(1):7073. doi: 10.1038/s41467-022-34793-6. PMID: 36400768; PMCID: PMC9674830

Restoring cellular magnesium balance through Cyclin M4 protects against acetaminophen-induced liver damage

González-Recio I, Simón J, Goikoetxea-Usandizaga N, Serrano-Maciá M, Mercado- Gómez M, Rodríguez-Agudo R, Lachiondo-Ortega S, Gil-Pitarch C, Fernández- Rodríguez C, Castellana D, Latasa MU, Abecia L, Anguita J, Delgado TC, Iruzubieta P, Crespo J, Hardy S, Petrov PD, Jover R, Avila MA, Martín C, Schaeper U, Tremblay ML, Dear JW, Masson S, McCain MV, Reeves HL, Andrade RJ, Lucena MI, Buccella D, Martínez-Cruz LA, Martínez-Chantar ML

Nat Commun. 2022 Nov 25;13(1):6816. doi: 10.1038/s41467-022-34262-0. PMID: 36433951; PMCID: PMC9700862

CryoEM structural exploration of catalytically active enzyme pyruvate carboxylase

López-Alonso JP, Lázaro M, Gil-Cartón D, Choi PH, Dodu A, Tong L, Valle M

Nat Commun. 2022 Oct 19;13(1):6185. doi: 10.1038/s41467-022-33987-2. Erratum in: Nat Commun. 2022 Nov 16;13(1):7009. PMID: 36261450; PMCID: PMC9581989

Mechanism of cooperative N-glycan processing by the multi-modular endoglycosidase EndoE

García-Alija M, Du JJ, Ordóñez I, Diz-Vallenilla A, Moraleda-Montoya A, Sultana N, Huynh CG, Li C, Donahue TC, Wang LX, Trastoy B, Sundberg EJ, Guerin ME

Nat Commun. 2022 Mar 3;13(1):1137. doi: 10.1038/s41467-022-28722-w. PMID: 35241669; PMCID: PMC8894350

Methionine adenosyltransferase 1a antisense oligonucleotides activate the liver-brown adipose tissue axis preventing obesity and associated hepatosteatosis

Sáenz de Urturi D, Buqué X, Porteiro B, Folgueira C, Mora A, Delgado TC, Prieto-Fernández E, Olaizola P, Gómez-Santos B, Apodaka-Biguri M, González- Romero F, Nieva-Zuluaga A, Ruiz de Gauna M, Goikoetxea-Usandizaga N, García-Rodríguez JL, Gutierrez de Juan V, Aurrekoetxea I, Montalvo-Romeral V, Novoa EM, Martín-Guerrero I, Varela-Rey M, Bhanot S, Lee R, Banales JM, Syn WK, Sabio G, Martínez-Chantar ML, Nogueiras R, Aspichueta

Nat Commun. 2022 Mar 1;13(1):1096. doi: 10.1038/s41467-022-28749-z. PMID: 35232994; PMCID: PMC8888704

Depletion of mitochondrial methionine adenosyltransferase α1 triggers mitochondrial dysfunction in alcohol-associated liver disease

Barbier-Torres L, Murray B, Yang JW, Wang J, Matsuda M, Robinson A, Binek A, Fan W, Fernández-Ramos D, Lopitz-Otsoa F, Luque-Urbano M, Millet O, Mavila N, Peng H, Ramani K, Gottlieb R, Sun Z, Liangpunsakul S, Seki E, Van Eyk JE, Mato JM, Lu SC

Nat Commun. 2022 Jan 28;13(1):557. doi: 10.1038/s41467-022-28201-2. PMID: 35091576; PMCID: PMC8799735

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

Martínez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM

Hepatology. 2022 Oct;76(4):1121-1134. doi: 10.1002/hep.32427. Epub 2022 Mar 17. PMID: 35220605; PMCID: PMC9790568

Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids

Ruiz de Gauna M, Biancaniello F, González-Romero F, Rodrigues PM, Lapitz A, Gómez-Santos B, Olaizola P, Di Matteo S, Aurrekoetxea I, Labiano I, Nieva-Zuluaga A, Benito-Vicente A, Perugorria MJ, Apodaka-Biguri M, Paiva NA, Sáenz de Urturi D, Buqué X, Delgado I, Martín C, Azkargorta M, Elortza F, Calvisi DF, Andersen JB, Alvaro D, Cardinale V, Bujanda L, Banales JM, Aspichueta P

Hepatology. 2022 Dec;76(6):1617-1633. doi: 0.1002/hep.32344. Epub 2022 Feb 8. PMID: 35030285; PMCID: PMC979056

Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma

Rackles E, Lopez PH, Falcon-Perez JM

Semin Cancer Biol. 2022 Dec;87:148-159. doi: 10.1016/j.semcancer.2022.11.004. Epub 2022 Nov 11. PMID: 36375777

Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients

Capelle CM, Ciré S, Domingues O, Ernens I, Hedin F, Fischer A, Snoeck CJ, Ammerlaan W, Konstantinou M, Grzyb K, Skupin A, Carty CL, Hilger C, Gilson G, Celebic A, Wilmes P, Del Sol A, Kaplan IM, Betsou F, Abdelrahman T, Cosma A, Vaillant M, Fagherazzi G, Ollert M, Hefeng FQ

Cell Rep Med. 2022 Mar 29;3(4):100600. doi: 10.1016/j.xcrm.2022.100600. PMID: 35480624; PMCID: PMC8960124

Synthetic Zwitterionic Streptococcus pneumoniae Type 1 Oligosaccharides Carrying Labile O-Acetyl Esters

Wang Z, Gimeno A, Lete MG, Overkleeft HS, van der Marel GA, Chiodo F, Jiménez-Barbero J, Codée JDC

Angew Chem Int Ed Engl. 2023 Jan 2;62(1):e202211940. doi: 10.1002/anie.202211940. Epub 2022 Dec 1. PMID: 36350770; PMCID: PMC10107948

Protoglobin-Catalyzed Formation of cis-Trifluoromethyl-Substituted Cyclopropanes by Carbene Transfer

Schaus L, Das A, Knight AM, Jimenez-Osés G, Houk KN, Garcia-Borràs M, Arnold FH, Huang X

Angew Chem Int Ed Engl. 2023 Jan 23;62(4):e202208936. doi: 10.1002/anie.202208936. Epub 2022 Dec 19. PMID: 36533936; PMCID: PMC9894577

The SARS-CoV-2 Spike Glycoprotein Directly Binds Exogeneous Sialic Acids: A NMR View

Unione L, Moure MJ, Lenza MP, Oyenarte I, Ereño-Orbea J, Ardá A, Jiménez- Barbero J

Angew Chem Int Ed Engl. 2022 Apr 25;61(18):e202201432. doi:10.1002/anie.202201432. Epub 2022 Mar 7. PMID: 35191576; PMCID: PMC9074024

Platform for Orthogonal N-Cysteine-Specific Protein Modification Enabled by Cyclopropenone Reagents

Istrate A, Geeson MB, Navo CD, Sousa BB, Marques MC, Taylor RJ, Journeaux T, Oehler SR, Mortensen MR, Deery MJ, Bond AD, Corzana F, Jiménez-Osés G, Bernardes GJL

J Am Chem Soc. 2022 Jun 15;144(23):10396-10406. doi: 10.1021/jacs.2c02185. Epub 2022 Jun 5. PMID: 35658467; PMCID: PMC9490850

Introducing the Catalytic Amination of Silanes via Nitrene Insertion

Rodríguez AM, Pérez-Ruíz J, Molina F, Poveda A, Pérez-Soto R, Maseras F, Díaz-Requejo MM, Pérez PJ

J Am Chem Soc. 2022 Jun 15;144(23):10608-10614. doi: 10.1021/jacs.2c03739. Epub 2022 Jun 1. PMID: 35648453; PMCID: PMC9490852

Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry

Ferhati X, Jiménez-Moreno E, Hoyt EA, Salluce G, Cabeza-Cabrerizo M, Navo CD, Compañón I, Akkapeddi P, Matos MJ, Salaverri N, Garrido P, Martínez A, Laserna V, Murray TV, Jiménez-Osés G, Ravn P, Bernardes GJL, Corzana F

J Am Chem Soc. 2022 Mar 30;144(12):5284-5294. doi: 10.1021/jacs.1c07675. Epub 2022 Mar 16. PMID: 35293206; PMCID: PMC8972253

Ultrasmall Manganese Ferrites for In Vivo Catalase Mimicking Activity and Multimodal Bioimaging

Carregal-Romero S, Miguel-Coello AB, Martínez-Parra L, Martí-Mateo Y, Hernansanz-Agustín P, Fernández-Afonso Y, Plaza-García S, Gutiérrez L, Muñoz- Hernández MDM, Carrillo-Romero J, Piñol-Cancer M, Lecante P, Blasco-Iturri Z, Fadón L, Almansa-García AC, Möller M, Otaegui D, Enríquez JA, Groult H, Ruíz- Cabello J

Small. 2022 Apr;18(16):e2106570. doi: 10.1002/smll.202106570. Epub 2022 Mar 8. PMID: 35263020

Neural network learning defines glioblastoma features to be of neural crest perivascular or radial glia lineages

Hu Y, Jiang Y, Behnan J, Ribeiro MM, Kalantzi C, Zhang MD, Lou D, Häring M, Sharma N, Okawa S, Del Sol A, Adameyko I, Svensson M, Persson O, Ernfors P

Sci Adv. 2022 Jun 10;8(23):eabm6340. doi: 10.1126/sciadv.abm6340. Epub 2022 Jun 8. PMID: 35675414; PMCID: PMC9177076

A switch from α-helical to β-strand conformation during co-translational protein folding

Agirrezabala X, Samatova E, Macher M, Liutkute M, Maiti M, Gil-Carton D, Novacek J, Valle M, Rodnina MV

EMBO J. 2022 Feb 15;41(4):e109175. doi: 10.15252/embj.2021109175. Epub 2022 Jan 7. PMID: 34994471; PMCID: PMC8844987

Density and Neuronal Biomarkers in Cancer

Ali SR, Jordan M, Nagarajan P, Amit M

Cancers (Basel). 2022 Oct 1;14(19):4817. doi: 10.3390/cancers14194817. PMID: 36230740; PMCID: PMC9561962

The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation

Ladewig E, Michelini F, Jhaveri K, Castel P, Carmona J, Fairchild L, Zuniga AG, Arruabarrena-Aristorena A, Cocco E, Blawski R, Kittane S, Zhang Y, Sallaku M, Baldino L, Hristidis V, Chandarlapaty S, Abdel-Wahab O, Leslie C, Scaltriti M, Toska E

Cancer Res. 2022 Jun 15;82(12):2269-2280. doi: 10.1158/0008-5472.CAN-22-0446. PMID: 35442400; PMCID: PMC9354703

Chaperone-Mediated Autophagy Controls Proteomic and Transcriptomic Pathways to Maintain Glioma Stem Cell Activity

Auzmendi-Iriarte J, Otaegi-Ugartemendia M, Carrasco-Garcia E, Azkargorta M, Diaz A, Saenz-Antoñanzas A, Andermatten JA, Garcia-Puga M, Garcia I, Elua-Pinin A, Ruiz I, Sampron N, Elortza F, Cuervo AM, Matheu A

Cancer Res. 2022 Apr 1;82(7):1283-1297. doi: 10.1158/0008-5472.CAN-21-2161. PMID: 35131870; PMCID: PMC9359743

New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

Colyn L,. Alvarez-Sola G, Latasa MU, Uriarte I, Herranz JM, Arechederra M, Vlachogiannis G, Rae C, Pineda-Lucena A, Casadei-Gardini A, Pedica F, Aldrighetti L, López-López A, López-Gonzálvez A, Barbas C, Ciordia S, Van Liempd SM, Falcón-Pérez JM, Urman J, Sangro B, Vicent S, Iraburu MJ, Prosper F, Nelson LJ, Banales JM, Martinez-Chantar ML, Marin JJG, Braconi C, Trautwein C, Corrales FJ, Cubero FJ, Berasain C, Fernandez-Barrena MG, Avila MA

J Exp Clin Cancer Res. 2022 May 26;41(1):183. doi: 10.1186/s13046-022-02386-2. PMID: 35619118; PMCID: PMC9134609

Reviews

Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies

Camilleri M, Zhernakova A, Bozzarelli I, D'Amato M. Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies

Nat Rev Gastroenterol Hepatol. 2022 Nov;19(11):689-702. doi: 10.1038/s41575-022-00662-2. Epub 2022 Aug 10. PMID: 35948782

Read the article

HuR-targeted agents: An insight into medicinal chemistry, biophysical, computational studies and pharmacological effects on cancer models

Assoni G, La Pietra V, Digilio R, Ciani C, Licata NV, Micaelli M, Facen E, Tomaszewska W, Cerofolini L, Pérez-Ràfols A, Varela Rey M, Fragai M, Woodhoo A, Marinelli L, Arosio D, Bonomo I, Provenzani A, Seneci P

Adv Drug Deliv Rev. 2022 Feb;181:114088. doi: 10.1016/j.addr.2021.114088. Epub 2021 Dec 20. PMID: 34942276

Read the article

Editorial Activity

  • Joaquín Castilla
    Advisory Board

    Juan Anguita
    Editor Board

  • Óscar Millet
    Associate Editor

  • Óscar Millet
    Editor Board

  • Juan Anguita
    Editor Board

  • Malu Martínez Chantar
    Editor Board

  • Óscar Millet
    Editor Board

  • Rosa Barrio
    Editor Board

    Juan Anguita
    Senior Editor

    Óscar Millet
    Editor Board

  • Félix Elortza
    Editor Board

  • Malu Martínez Chantar
    Associate Editor

  • Asís Palazón
    Associate Editor

    Juan Anguita
    Guest Associate Editor

  • Joaquín Castilla
    Associate Editor

  • Rosa Barrio
    Associate Editor

  • María Vivanco
    Editor Board

  • Arkaitz Carracedo
    Consultant Editor

  • Jesús Jiménez-Barbero
    Associate Editor

  • Jesús Jiménez-Barbero
    Advisory Board

  • Malu Martínez Chantar
    Editor Board

  • Antonio Del Sol
    Editor Board

    Óscar Millet
    Editor Board

  • Félix Elortza
    Editor Board

  • Rosa Barrio
    Guest Editor

  • Edurne Berra
    Associate Editor

  • Juan Manuel Falcón
    Deputy Editor

  • Jesús Jiménez-Barbero
    Advisory Board

  • Jesús Jiménez-Barbero
    Advisory Board

  • Robert Kypta
    Editor Board

  • Jesús Jiménez-Barbero
    Editor Board

  • Óscar Millet
    Editor Board

  • Joaquín Castilla
    Editor Board

  • Joaquín Castilla
    Editor Board

  • Juan Anguita
    Editor Board

PhD Thesis

0 in progress

Collaboration RVCTI

0 RVCTI
(Basque Network)

Theses

Thesis Carmen Fernández Rodríguez

Carmen Fernández Rodríguez

Novel surface engineering approaches for protein crystallization and structural insights into the enzimes of reverse transsulfuration from the human pathogens Toxoplasma gondii and Pseudomonas aeruginosa.

Thesis Guillermo García Marquina

Guillermo García Marquina

Acyltransferase LovD as a Simvastatin synthase

Thesis Ariane Schaub Clerigué

Ariane Schaub Clerigué

PGC-driven transcriptional control of the cell secretome in prostate cancer: molecular and biological analysis

Thesis Javier Plou Izquierdo

Javier Plou Izquierdo

Label-free monitoring of tumor models by surface-enhanced raman scattering

Thesis Pilar Castellnou Arenas

Pilar Castellnou Arenas

Synthesis of positron emitter-labelled amino acids: Application to the investigation of metabolic preferences and vulnerabilities in a mouse prostate cancer model

Thesis Naroa Goikoetxea-Usandizaga

Naroa Goikoetxea-Usandizaga

Role of mitochondria in liver diseases

Thesis Miguel Tamayo Caro

Miguel Tamayo Caro

Neddylation in schwann cell myelination

Thesis Jon Imanol Quintana García

Jon Imanol Quintana García

NMR and molecular recognition: The interaction of human galectin-4 with the histo blood group antigens and with pathogen-associated molecules

Thesis Nicanor Zalba Olaizola

Nicanor Zalba Olaizola

On the effect of cosolutes and crowders in the stability and kinetic properties of proteins

Thesis Irene González Recio

Irene González Recio

Unveiling magnesioum homeostasis in liver diseases

Thesis Julia San Millán Gutiérrez

Julia San Millán Gutiérrez

Analysis of the essentialy of phosphatidylserine decarboxylase in endocrine resistant breast cancer cells

Thesis Carlos Miguel Díaz Domínguez

Carlos Miguel Díaz Domínguez

Estudio de la diversidad de variantes de las proteinas del prion de cérvidos, su capaciidad de malplegamiento en influencia sobre la emergencia de cepas con características distintivas

Thesis Orhi Barroso Gomila

Orhi Barroso Gomila

Development of biotin-based strategies to dissect the ubiquitin code

Thesis Sara Bertuzzi

Sara Bertuzzi

Lectin-Glycan Interactions: new NMR insights on the role of dynamics and presentation by using state-of-the-art NMR methodologies

Thesis Jone Ibáñez Pérez

Jone Ibáñez Pérez

Free and extracellular vesicle-associated micro RNAs from endometrial fluid as non-invasive diagnostic biomarkers of implantative endometrium

Thesis Gabriel Soares Guerra

Gabriel Soares Guerra

Vaccine and structural studies of Schmallenberg virus

Training – Doctoral Candidates

The CIC bioGUNE Advanced Training Program

Introduction to CIC bioGUNE RESEARCH for new PhD Candidates

October 2022

New Group Leader

Starting in January 2023

Raúl Pérez-Jiménez

Ikerbasque Professor

Synthetic Biology

2013



PhD - 2005

Dissemination: Press

Radio & TV

International Visibility

Organization of symposia

EMBO Workshop 2014

CIC bioGUNE
  • 115 asistentes
  • 60% internacional
  • 53% mujeres

EMBO Workshop 2016

Palacio Euskalduna - Bilbao
  • 179 asistentes
  • 70% internacional
  • 38% mujeres

EMBO Workshop 2014

Palacio Euskalduna - Bilbao
  • 200 asistentes
  • 70% internacional
  • 50% mujeres

Financiación Bilbao Ekintza

EACR 2020

Virtual
  • 301 asistentes
  • 87% internacional

EACR 2022

Palacio Euskalduna - Bilbao
  • 275 asistentes
  • 77% internacional
  • 61% mujeres

Confirmed 2024 & 2026

Euromar 2020

Virtual
  • 900 people

Bilbao-Bizkaia

Euromar 2024

Palacio Euskalduna - Bilbao
  • 1000 people
  • 400 posters

Outreach

Carrera solidaria contra el cáncer de mama

Carrera solidaria "Raras pero no invisibles"

April 29

Marcha contra el Cáncer (Vitoria)

October 9

Entrega de cuentos didácticos infantiles

II Curso OMICAS en el estudio de las enfermedades hepáticas y digestivas

October 5-6

Cuestación Anual AECC

May 12

Download PDF version